Phase i clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas

Mateusz Opyrchal, Ileana Aderca, Evanthia Galanis

Research output: Chapter in Book/Report/Conference proceedingChapter

30 Citations (Scopus)

Abstract

Despite many advances in cancer therapy, metastatic disease continues to be incurable in the majority of cancer patients. There ia an need for more efficient and less toxic treatments is this setting. Oncolytic virotherapy represents a novel promising direction in the treatment of cancer. Based on preclinical and clinical data, combination with standard chemotherapy has the potential to further increase the antitumor activity of oncolytic virotherapy in a synergistic manner. We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
Pages705-717
Number of pages13
Volume542
DOIs
StatePublished - 2009

Publication series

NameMethods in Molecular Biology
Volume542
ISSN (Print)10643745

Fingerprint

Mitomycin
Oncolytic Virotherapy
Adenoviridae
Sarcoma
Doxorubicin
Cisplatin
Clinical Trials
Drug Therapy
Neoplasms
Clinical Trials, Phase I
Poisons
Therapeutics
Injections
ONYX015

Keywords

  • Cisplatin chemotherapy
  • doxorubicin
  • mitomycin-C
  • oncolytic adenovirus
  • ONYX-015
  • sarcomas

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Phase i clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. / Opyrchal, Mateusz; Aderca, Ileana; Galanis, Evanthia.

Methods in Molecular Biology. Vol. 542 2009. p. 705-717 (Methods in Molecular Biology; Vol. 542).

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{7b1e3a40db5e41df86f98a982a4b27b1,
title = "Phase i clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas",
abstract = "Despite many advances in cancer therapy, metastatic disease continues to be incurable in the majority of cancer patients. There ia an need for more efficient and less toxic treatments is this setting. Oncolytic virotherapy represents a novel promising direction in the treatment of cancer. Based on preclinical and clinical data, combination with standard chemotherapy has the potential to further increase the antitumor activity of oncolytic virotherapy in a synergistic manner. We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas.",
keywords = "Cisplatin chemotherapy, doxorubicin, mitomycin-C, oncolytic adenovirus, ONYX-015, sarcomas",
author = "Mateusz Opyrchal and Ileana Aderca and Evanthia Galanis",
year = "2009",
doi = "10.1007/978-1-59745-561-9_35",
language = "English (US)",
isbn = "9781934115855",
volume = "542",
series = "Methods in Molecular Biology",
pages = "705--717",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Phase i clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas

AU - Opyrchal, Mateusz

AU - Aderca, Ileana

AU - Galanis, Evanthia

PY - 2009

Y1 - 2009

N2 - Despite many advances in cancer therapy, metastatic disease continues to be incurable in the majority of cancer patients. There ia an need for more efficient and less toxic treatments is this setting. Oncolytic virotherapy represents a novel promising direction in the treatment of cancer. Based on preclinical and clinical data, combination with standard chemotherapy has the potential to further increase the antitumor activity of oncolytic virotherapy in a synergistic manner. We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas.

AB - Despite many advances in cancer therapy, metastatic disease continues to be incurable in the majority of cancer patients. There ia an need for more efficient and less toxic treatments is this setting. Oncolytic virotherapy represents a novel promising direction in the treatment of cancer. Based on preclinical and clinical data, combination with standard chemotherapy has the potential to further increase the antitumor activity of oncolytic virotherapy in a synergistic manner. We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas.

KW - Cisplatin chemotherapy

KW - doxorubicin

KW - mitomycin-C

KW - oncolytic adenovirus

KW - ONYX-015

KW - sarcomas

UR - http://www.scopus.com/inward/record.url?scp=67650296738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650296738&partnerID=8YFLogxK

U2 - 10.1007/978-1-59745-561-9_35

DO - 10.1007/978-1-59745-561-9_35

M3 - Chapter

SN - 9781934115855

VL - 542

T3 - Methods in Molecular Biology

SP - 705

EP - 717

BT - Methods in Molecular Biology

ER -